281 related articles for article (PubMed ID: 36422682)
1. From Stem to Sternum: The Role of Shp2 in the Skeleton.
Jensen NR; Kelly RR; Kelly KD; Khoo SK; Sidles SJ; LaRue AC
Calcif Tissue Int; 2023 Apr; 112(4):403-421. PubMed ID: 36422682
[TBL] [Abstract][Full Text] [Related]
2. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract][Full Text] [Related]
4. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials.
Song Y; Zhao M; Zhang H; Yu B
Pharmacol Ther; 2022 Feb; 230():107966. PubMed ID: 34403682
[TBL] [Abstract][Full Text] [Related]
5. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.
Yuan X; Bu H; Zhou J; Yang CY; Zhang H
J Med Chem; 2020 Oct; 63(20):11368-11396. PubMed ID: 32460492
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule Modulators Targeting SHP2 for Cancer Therapy.
Mi D; Li Y; Chen Y
Anticancer Agents Med Chem; 2023; 23(5):498-504. PubMed ID: 36154594
[TBL] [Abstract][Full Text] [Related]
8. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3.
Agazie YM; Movilla N; Ischenko I; Hayman MJ
Oncogene; 2003 Oct; 22(44):6909-18. PubMed ID: 14534538
[TBL] [Abstract][Full Text] [Related]
9. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review of SHP2 and its role in cancer.
Asmamaw MD; Shi XJ; Zhang LR; Liu HM
Cell Oncol (Dordr); 2022 Oct; 45(5):729-753. PubMed ID: 36066752
[TBL] [Abstract][Full Text] [Related]
11. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L
J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320
[TBL] [Abstract][Full Text] [Related]
12. The Cell-Specific Role of SHP2 in Regulating Bone Homeostasis and Regeneration Niches.
Zhang J; Ye C; Zhu Y; Wang J; Liu J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768520
[TBL] [Abstract][Full Text] [Related]
13. [The Biological Function of SHP2 in Human Disease].
Li SM
Mol Biol (Mosk); 2016; 50(1):27-33. PubMed ID: 27028808
[TBL] [Abstract][Full Text] [Related]
14. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
Tani H; Kurita S; Miyamoto R; Ochiai K; Tamura K; Bonkobara M
Vet Comp Oncol; 2020 Jun; 18(2):161-168. PubMed ID: 31339650
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types.
Vazhappilly CG; Saleh E; Ramadan W; Menon V; Al-Azawi AM; Tarazi H; Abdu-Allah H; El-Shorbagi AN; El-Awady R
Invest New Drugs; 2019 Apr; 37(2):252-261. PubMed ID: 29947013
[TBL] [Abstract][Full Text] [Related]
16. Strategies to overcome drug resistance using SHP2 inhibitors.
Liu M; Gao S; Elhassan RM; Hou X; Fang H
Acta Pharm Sin B; 2021 Dec; 11(12):3908-3924. PubMed ID: 35024315
[TBL] [Abstract][Full Text] [Related]
17. Protein Tyrosine Phosphatase Non-Receptor 11 (
Richards CE; Elamin YY; Carr A; Gately K; Rafee S; Cremona M; Hanrahan E; Smyth R; Ryan D; Morgan RK; Kennedy S; Hudson L; Fay J; O'Byrne K; Hennessy BT; Toomey S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445722
[No Abstract] [Full Text] [Related]
18. Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1.
Kurupi R; Floros KV; Jacob S; Chawla AT; Cai J; Hu B; Puchalapalli M; Coon CM; Khatri R; Crowther GS; Egan RK; Murchie E; Greninger P; Dalton KM; Ghotra MS; Boikos SA; Koblinski JE; Harada H; Sun Y; Morgan IM; Basu D; Dozmorov MG; Benes CH; Faber AC
Cancer Res Commun; 2022 Sep; 2(9):1061-1074. PubMed ID: 36506869
[TBL] [Abstract][Full Text] [Related]
19. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
20. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
